SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Senior Staff Writer

Tristan is BioSpace‘s senior staff writer. Based in Metro Manila, Tristan has more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Pictured: GSK's headquarters in West London/iStock
Policy
GSK Appeals Delaware Court’s Decision in Zantac Cases as Plaintiff Drops Lawsuit
On Monday, GSK reported that a plaintiff voluntarily dropped her Zantac case against the company and that it is in the process of appealing a Delaware State Court’s decision to admit expert testimony in other cases.
June 11, 2024
 · 
2 min read
 · 
Tristan Manalac
External view of Eli Lilly's world headquarters in Indianapolis
Drug Development
Lilly Sees More Zepbound Out-of-Pocket Payments as Obesity Pill Nears Phase III Readout
More patients are having to pay out-of-pocket for Eli Lilly’s weight-loss medication Zepbound than they did for type 2 diabetes drug Mounjaro, according to Lilly USA President Patrik Jonsson.
June 11, 2024
 · 
2 min read
 · 
Tristan Manalac
FDA signage at its headquarters in Maryland
FDA
Ipsen, Genfit’s Elafibranor Wins FDA Approval for Primary Biliary Cholangitis
Ipsen and Genfit’s elafibranor will now be marketed as Iqirvo and is the first new medicine approved in nearly a decade for the treatment of the rare liver disease, according to the companies.
June 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Facade of Moderna's building in Massachusetts
Drug Development
Moderna’s COVID-Flu Combo Shot Beats Separate Vaccines in Phase III Study
Moderna’s combination vaccine candidate for COVID-19 and influenza outperformed licensed vaccines in older adults, according to late-stage results reported on Monday.
June 10, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Eli Lilly Campus in San Diego
Drug Development
Lilly’s Tirzepatide Improves Liver Fibrosis in Phase II MASH Trial
Lilly’s tirzepatide achieved an absence of metabolic dysfunction-associated steatohepatitis without the worsening of fibrosis in more than 50% of patients in a mid-stage study, the company reported Saturday.
June 10, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Entrance to Pfizer's office in Belgium
Drug Development
Pfizer’s Paxlovid Ineffective Against Long COVID Using 15-Day Regimen: Study
While a prolonged, 15-day regimen of Paxlovid is safe, it appears to be ineffective at lowering the symptoms of long COVID, according to results of a Phase II trial funded by Pfizer and conducted by Stanford Medicine.
June 10, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: GSK's office in Poznan, Poland/iStock, W
FDA
GSK’s RSV Shot Wins Expanded FDA Approval for At-Risk Adults Aged 50 to 59
The FDA on Friday approved GSK’s application to use Arexvy to vaccinate adults aged 50 to 59 years who are at increased risk of developing severe respiratory syncytial virus.
June 10, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Boehringer Ingelheim's office in California
Drug Development
Boehringer, Zealand Heat Up MASH Race With Strong Phase II Data
The companies announced Friday that their candidate survodutide, which is licensed to Boehringer Ingelheim from Zealand Pharma, improved fibrosis in more than 50% of treated patients with metabolic dysfunction-associated steatohepatitis.
June 7, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Boardroom overlooking a city/iStock, ism
Deals
Vanda Gets $466M Unsolicited Offer from Cycle Amid Ongoing Row with FDA
After rejecting a previous takeover offer from Future Pak, Vanda Pharmaceuticals is now fielding another acquisition proposal from Cycle Pharmaceuticals, which values the biotech at $8 per share.
June 7, 2024
 · 
2 min read
 · 
Tristan Manalac
AbbVie's office in South San Francisco, California
Drug Development
AbbVie Sees Early ROI on $10B Immunogen Buy in Phase II Ovarian Cancer Win
AbbVie’s antibody-drug conjugate Elahere, developed by ImmunoGen, elicited a nearly 52% objective response rate in heavily pretreated patients with folate receptor-alpha-positive, platinum-sensitive ovarian cancer.
June 7, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Eli Lilly's biotechnology center in San
Policy
FDA Raises Concerns About Lilly’s Donanemab Alzheimer’s Candidate Ahead of Adcomm
In advance of an advisory committee meeting on Monday, the FDA’s internal reviewers have raised issues regarding Eli Lilly’s Alzheimer’s disease candidate donanemab, flagging problems with its study design and safety outcomes.
June 7, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Amgen's office in Tampa, Florida
Drug Development
Amgen Phase III Win Positions Uplizna for Label Expansion in Rare Autoimmune Disease
Amgen’s CD19-directed antibody Uplizna in a late-stage study showed it can suppress the risk of flares by nearly 90% in patients with IgG4-related disease, the company announced Wednesday.
June 6, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Novo Nordisk's corporate headquarters in Denmark
Drug Development
Novo’s Ozempic, Wegovy to Face Stiff Generic Competition in China: Reuters
Novo Nordisk will face strong generic competition from at least 15 companies in China for its blockbuster GLP-1 receptor agonist products Wegovy and Ozempic, according to Reuters.
June 6, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Nasdaq signage and building in New York City
Deals
Telix Targets $200M IPO in Hot Radiopharma Market as Biotech Nasdaq Offerings Slow
Telix Pharmaceuticals is looking to cash in on radiopharmaceuticals, which have emerged as one of the hottest spaces in oncology, with an initial public offering to help support its pipeline of targeted radiation products.
June 6, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Facade of Moderna's building in Massachusetts
Policy
Moderna’s mRNA Candidate Joins FDA’s Accelerator Program for Rare Diseases
Moderna on Thursday said its investigational mRNA-based therapy for methylmalonic acidemia has been selected for the FDA’s accelerator program for rare diseases, dubbed START.
June 6, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More